Natera MCED Assay Receives FDA Breakthrough Device Designation

Key Takeaways

• Natera's investigational blood-based multi-cancer screening assay received FDA Breakthrough Device designation in the United States.
• The FDA considered assay sensitivity, specificity, and cancer signal origin in evaluating the designation.
• No numerical assay-performance findings or marketing authorization were reported for its multi-cancer early detection assay.

Natera’s multi-cancer early detection (MCED) assay analyzes cell-free deoxyribonucleic acid (DNA) in blood and is intended to screen for multiple cancers. And now, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its assay. The FDA assessed data from 12 cancer types and considered sensitivity, specificity, and cancer signal origin (CSO) performance.

The Breakthrough Devices program is intended to accelerate device development, assessment, and review. Designation itself is not FDA marketing authorization. The assay remains a proposed screening approach; its performance and effect on clinical outcomes cannot be determined from this regulatory announcement.

Clinician Questions

Which FDA authorization pathways could follow Breakthrough Device designation for Natera’s multi-cancer early detection assay?

Natera describes the Breakthrough Devices program as accelerating development, assessment, and review toward premarket approval, 510(k) clearance, or De Novo marketing authorization. These are potential review routes, not authorizations the assay has received.